The cardiovascular manifestations of HIV infections

Steven E Lipshultz, Stacy D. Fisher, Tracie L Miller, Tanvi S. Sharma, Angela N. Milton

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Cardiovascular illness is common in patients with human immunodeficiency virus (HIV) infection, particularly late in the disease course. As better therapy improves longevity for patients with HIV infection, symptomatic heart failure and related cardiovascular morbidity and mortality are becoming important global health concerns. The incidence of symptomatic heart failure among HIV-infected people followed for 2 to 5 years is 8% to 10%, suggesting that there may be about 3 million prevalent cases of symptomatic HIV-related heart failure. There are many different manifestations of cardiac disease in HIV-infected individuals, including left ventricular systolic dysfunction or cardiomyopathy, pericardial effusion, infective endocarditis, cardiovascular malignancy, vasculitis, atherosclerosis, and autonomic dysfunction. Cardiac disease may result from HIV itself, other infectious etiologies, or may be accelerated by the effects of the antiretroviral agents used to treat HIV infection. In this paper, we will examine the various cardiovascular manifestations of HIV disease and its treatment, review the prevalence, pathogenesis, and treatment options, and discuss preventive measures and monitoring to identify preclinical cardiac disease early on in its course.

Original languageEnglish
Pages (from-to)5-23
Number of pages19
JournalDialogues in Cardiovascular Medicine
Volume12
Issue number1
StatePublished - Oct 3 2007

Fingerprint

Virus Diseases
HIV
Heart Diseases
Heart Failure
Anti-Retroviral Agents
Pericardial Effusion
Left Ventricular Dysfunction
Vasculitis
Endocarditis
Cardiomyopathies
Atherosclerosis
Therapeutics
Morbidity
Mortality
Incidence

Keywords

  • AIDS
  • Atherosclerosis
  • Cardiomyopathy
  • Cardiovascular disease
  • Highly active antiretroviral therapy
  • HIV

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Lipshultz, S. E., Fisher, S. D., Miller, T. L., Sharma, T. S., & Milton, A. N. (2007). The cardiovascular manifestations of HIV infections. Dialogues in Cardiovascular Medicine, 12(1), 5-23.

The cardiovascular manifestations of HIV infections. / Lipshultz, Steven E; Fisher, Stacy D.; Miller, Tracie L; Sharma, Tanvi S.; Milton, Angela N.

In: Dialogues in Cardiovascular Medicine, Vol. 12, No. 1, 03.10.2007, p. 5-23.

Research output: Contribution to journalArticle

Lipshultz, SE, Fisher, SD, Miller, TL, Sharma, TS & Milton, AN 2007, 'The cardiovascular manifestations of HIV infections', Dialogues in Cardiovascular Medicine, vol. 12, no. 1, pp. 5-23.
Lipshultz SE, Fisher SD, Miller TL, Sharma TS, Milton AN. The cardiovascular manifestations of HIV infections. Dialogues in Cardiovascular Medicine. 2007 Oct 3;12(1):5-23.
Lipshultz, Steven E ; Fisher, Stacy D. ; Miller, Tracie L ; Sharma, Tanvi S. ; Milton, Angela N. / The cardiovascular manifestations of HIV infections. In: Dialogues in Cardiovascular Medicine. 2007 ; Vol. 12, No. 1. pp. 5-23.
@article{585ccfceb0c14c67b146530750fa1736,
title = "The cardiovascular manifestations of HIV infections",
abstract = "Cardiovascular illness is common in patients with human immunodeficiency virus (HIV) infection, particularly late in the disease course. As better therapy improves longevity for patients with HIV infection, symptomatic heart failure and related cardiovascular morbidity and mortality are becoming important global health concerns. The incidence of symptomatic heart failure among HIV-infected people followed for 2 to 5 years is 8{\%} to 10{\%}, suggesting that there may be about 3 million prevalent cases of symptomatic HIV-related heart failure. There are many different manifestations of cardiac disease in HIV-infected individuals, including left ventricular systolic dysfunction or cardiomyopathy, pericardial effusion, infective endocarditis, cardiovascular malignancy, vasculitis, atherosclerosis, and autonomic dysfunction. Cardiac disease may result from HIV itself, other infectious etiologies, or may be accelerated by the effects of the antiretroviral agents used to treat HIV infection. In this paper, we will examine the various cardiovascular manifestations of HIV disease and its treatment, review the prevalence, pathogenesis, and treatment options, and discuss preventive measures and monitoring to identify preclinical cardiac disease early on in its course.",
keywords = "AIDS, Atherosclerosis, Cardiomyopathy, Cardiovascular disease, Highly active antiretroviral therapy, HIV",
author = "Lipshultz, {Steven E} and Fisher, {Stacy D.} and Miller, {Tracie L} and Sharma, {Tanvi S.} and Milton, {Angela N.}",
year = "2007",
month = "10",
day = "3",
language = "English",
volume = "12",
pages = "5--23",
journal = "Dialogues in Cardiovascular Medicine",
issn = "1272-9949",
publisher = "Servier International",
number = "1",

}

TY - JOUR

T1 - The cardiovascular manifestations of HIV infections

AU - Lipshultz, Steven E

AU - Fisher, Stacy D.

AU - Miller, Tracie L

AU - Sharma, Tanvi S.

AU - Milton, Angela N.

PY - 2007/10/3

Y1 - 2007/10/3

N2 - Cardiovascular illness is common in patients with human immunodeficiency virus (HIV) infection, particularly late in the disease course. As better therapy improves longevity for patients with HIV infection, symptomatic heart failure and related cardiovascular morbidity and mortality are becoming important global health concerns. The incidence of symptomatic heart failure among HIV-infected people followed for 2 to 5 years is 8% to 10%, suggesting that there may be about 3 million prevalent cases of symptomatic HIV-related heart failure. There are many different manifestations of cardiac disease in HIV-infected individuals, including left ventricular systolic dysfunction or cardiomyopathy, pericardial effusion, infective endocarditis, cardiovascular malignancy, vasculitis, atherosclerosis, and autonomic dysfunction. Cardiac disease may result from HIV itself, other infectious etiologies, or may be accelerated by the effects of the antiretroviral agents used to treat HIV infection. In this paper, we will examine the various cardiovascular manifestations of HIV disease and its treatment, review the prevalence, pathogenesis, and treatment options, and discuss preventive measures and monitoring to identify preclinical cardiac disease early on in its course.

AB - Cardiovascular illness is common in patients with human immunodeficiency virus (HIV) infection, particularly late in the disease course. As better therapy improves longevity for patients with HIV infection, symptomatic heart failure and related cardiovascular morbidity and mortality are becoming important global health concerns. The incidence of symptomatic heart failure among HIV-infected people followed for 2 to 5 years is 8% to 10%, suggesting that there may be about 3 million prevalent cases of symptomatic HIV-related heart failure. There are many different manifestations of cardiac disease in HIV-infected individuals, including left ventricular systolic dysfunction or cardiomyopathy, pericardial effusion, infective endocarditis, cardiovascular malignancy, vasculitis, atherosclerosis, and autonomic dysfunction. Cardiac disease may result from HIV itself, other infectious etiologies, or may be accelerated by the effects of the antiretroviral agents used to treat HIV infection. In this paper, we will examine the various cardiovascular manifestations of HIV disease and its treatment, review the prevalence, pathogenesis, and treatment options, and discuss preventive measures and monitoring to identify preclinical cardiac disease early on in its course.

KW - AIDS

KW - Atherosclerosis

KW - Cardiomyopathy

KW - Cardiovascular disease

KW - Highly active antiretroviral therapy

KW - HIV

UR - http://www.scopus.com/inward/record.url?scp=34848850700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848850700&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:34848850700

VL - 12

SP - 5

EP - 23

JO - Dialogues in Cardiovascular Medicine

JF - Dialogues in Cardiovascular Medicine

SN - 1272-9949

IS - 1

ER -